Natural Alternatives International Inc当前公司基本面数据相对稳定,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在药品行业排名115/159位。机构持股占比非常高,中期看,股价处于上升通道。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
Natural Alternatives International Inc评分
相关信息
行业排名
115 / 159
全市场排名
359 / 4521
所属行业
药品
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Natural Alternatives International Inc亮点
亮点风险
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.